Leuprorelin/norethisterone acetate

Last updated

Leuprorelin/norethisterone acetate
Combination of
Leuprorelin Gonadotropin-releasing hormone agonist
Norethisterone acetate Progestin
Clinical data
Trade names Lupaneta Pack
Other namesLeuprolide/norethindrone acetate
AHFS/Drugs.com Micromedex Detailed Consumer Information
License data
Routes of
administration 		Intramuscular and by mouth
ATC code
  • None
Legal status
Legal status

Leuprorelin/norethisterone acetate, also known as leuprolide/norethindrone acetate and sold under the brand name Lupaneta Pack, is a co-packaged medication used to treat endometriosis. [1] It contains leuprorelin as the acetate, a gonadotropin-releasing hormone agonist, and norethisterone acetate, a progestin. [1] The leuprorelin is given by intramuscular injection and the norethisterone acetate is taken by mouth. [1]

Contents

The co-packaged medication was approved for medical use in the United States in December 2012. [2]

Medical uses

Leuprorelin/norethisterone acetate is indicated for the initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. [1]

References

  1. 1 2 3 4 5 "Lupaneta Pack (leuprolide acetate for depot suspension; norethindrone acetate tablets), co-packaged for intramuscular use and for oral use, respectively Initial U.S. Approval: 2012". DailyMed. Archived from the original on 2 February 2023. Retrieved 1 February 2023.
  2. ↑ "Drug Approval Package: Lupaneta Pack (leuprolide acetate for depot suspension and norethindrone acetate) NDA #203696". U.S. Food and Drug Administration (FDA). 9 September 2013. Archived from the original on 5 April 2021. Retrieved 1 February 2023.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.